D. Brent Polk Division of Pediatric Gastroenterology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee.
Tennessee Department of Health, Nashville, Tennessee.
Clin Infect Dis. 2018 Jun 1;66(12):1892-1898. doi: 10.1093/cid/cix1128.
Culture-independent diagnostic tests (CIDTs) are increasingly used to identify enteric pathogens. However, foodborne illness surveillance systems have relied upon culture confirmation to estimate disease burden and identify outbreaks through molecular subtyping. This study examined the impacts of CIDT and estimated costs for culture verification of Shigella, Salmonella, Shiga toxin-producing Escherichia coli (STEC), and Campylobacter at the Tennessee Department of Health Public Health Laboratory (PHL).
This observational study included laboratory and epidemiological surveillance data collected between years 2013-2016 from patients with the reported enteric illness. We calculated pathogen recovery at PHL based on initial diagnostic test type reported at the clinical laboratory. Adjusted prevalence ratios (PRs) and 95% confidence intervals (CIs) were estimated with modified Poisson regression. Estimates of cost were calculated for pathogen recovery from CIDT-positive specimens compared to recovery from culture-derived isolates.
During the study period, PHL received 5553 specimens from clinical laboratories from patients with the enteric illness. Pathogen recovery was 57% (984/1713) from referred CIDT-positive stool specimens and 95% (3662/3840) from culture-derived isolates (PR, 0.61 [95% CI, .56-.66]). Pathogen recovery from CIDT-positive specimens varied based on pathogen type: Salmonella (72%), Shigella (64%), STEC (57%), and Campylobacter (26%). Compared to stool culture-derived isolates, the cost to recover pathogens from 100 CIDT-positive specimens was higher for Shigella (US $6192), Salmonella (US $18373), and STEC (US $27783).
Pathogen recovery was low from CIDT-positive specimens for enteric bacteria. This has important implications for the current enteric disease surveillance system, outbreak detection, and costs for public health programs.
非培养诊断检测(CIDT)越来越多地用于鉴定肠道病原体。然而,食源性疾病监测系统一直依赖于培养确认来估计疾病负担,并通过分子分型来识别暴发。本研究在田纳西州卫生署公共卫生实验室(PHL)检查了 CIDT 的影响,并估算了对志贺氏菌、沙门氏菌、产志贺毒素大肠杆菌(STEC)和弯曲菌进行培养验证的成本。
本观察性研究包括 2013-2016 年间从报告有肠道疾病的患者中收集的实验室和流行病学监测数据。我们根据临床实验室报告的初始诊断检测类型,计算 PHL 上的病原体回收率。采用修正泊松回归估计调整后的患病率比(PR)和 95%置信区间(CI)。与从培养衍生分离株中恢复相比,从 CIDT 阳性标本中恢复病原体的成本估计。
在研究期间,PHL 从临床实验室收到了 5553 份来自有肠道疾病的患者的标本。从转诊的 CIDT 阳性粪便标本中获得了 57%(984/1713)的病原体回收率,从培养衍生分离株中获得了 95%(3662/3840)(PR,0.61[95%CI,0.56-0.66])。从 CIDT 阳性标本中获得病原体的回收率因病原体类型而异:沙门氏菌(72%)、志贺氏菌(64%)、STEC(57%)和弯曲菌(26%)。与粪便培养衍生分离株相比,从 100 份 CIDT 阳性标本中恢复病原体的成本对于志贺氏菌(6192 美元)、沙门氏菌(18373 美元)和 STEC(27783 美元)更高。
从 CIDT 阳性标本中获得肠道细菌的病原体回收率较低。这对当前的肠道疾病监测系统、暴发检测和公共卫生计划的成本都有重要影响。